|
|
|
| Research progress on prevention and treatment of central obesity |
| TU Chuanfa1, WANG Xinyi1, ZHANG Youyou1, ZHU Shuang1, WU Shan2, WANG Liangyou3
|
1. Taizhou First People's Hospital, Taizhou, Zhejiang 318020, China;
2. Yuhuan People's Hospital, Yuhuan, Zhejiang 317600, China;
3. Taizhou Center for Disease Control and Prevention (Taizhou Institute of Public Health Supervision), Taizhou, Zhejiang 318000, China |
|
|
|
|
Abstract Central obesity is characterized primarily by visceral fat accumulation, which increases the risk of metabolic complications and premature death. This study reviewed literature on central obesity published in databases such as PubMed and China National Knowledge Infrastructure from 2004 to 2024, reviewing advancements in its pathogenesis, diagnosis, and prevention/treatment. Regarding pathogenesis, abnormalities in epigenetic regulation, gut microbiota imbalance, dysfunction of the hypothalamic-pituitary-adrenal axis and the gut-brain axis contribute to abnormal visceral fat accumulation, leading to central obesity. In terms of diagnosis, the optimized application of the International Diabetes Federation's waist circumference criteria, along with Chinese indicators such as waist-to-hip ratio and waist-to-height ratio, enhances early identification and diagnostic accuracy. For prevention and treatment, lifestyle interventions including energy-restricted diets, intermittent fasting, and optimized exercise regimens combined with multidimensional strategies involving pharmacotherapy and bariatric surgery, can effectively improve central obesity. With advances in precision medicine and translational medicine, the management of central obesity is shifting from empirical medicine to precision medicine and from single-treatment approaches to comprehensive interventions, providing evidence-based foundations for refining strategies aimed at central obesity prevention and control.
|
|
Received: 09 October 2025
Revised: 31 May 2026
Published: 27 July 2026
|
|
|
|
|
|
[1] Neeland I J,Ross R,Després J P,et al.Visceral and ectopic fat,atherosclerosis,and cardiometabolic disease:a position statement[J].Lancet Diabetes Endocrinol,2019,7(9):715-725.
[2] Pischon T,Boeing H,Hoffmann K,et al.General and abdominal adiposity and risk of death in Europe[J].N Engl J Med,2008,359(20):2105-2120.
[3] Nan J,Chen M L,Yuan H T,et al.Prevalence and influencing factors of central obesity among adults in China:China Nutrition And Health Surveillance(2015-2017)[J/OL].Nutrients,2024,16(16)[2026-05-31].https://doi.org/10.3390/nu16162623.
[4] 张晓帆,王惠君,苏畅,等.2000—2023年中国十省(自治区)成年居民超重肥胖及中心性肥胖的流行现况及趋势[J].卫生研究,2024,53(6):874-879.
[5] 马淑婧,张云飞,杨招庚,等.中国1993—2015年儿童青少年腰围及腹型肥胖流行趋势[J].中国学校卫生,2020,41(6):897-900.
[6] Wu J M,Frazier K,Zhang J F,et al.Emerging role of m6 A RNA methylation in nutritional physiology and metabolism[J/OL].Obes Rev,2020,21(1)[2026-05-31].https://doi.org/10.1111/obr.12942.
[7] Rouschop S,Karl T,Maas L,et al.Prenatal high fat diet alters DNA methylation and gene expression of metabolic genes in mouse offspring[J/OL].Toxicol Lett,2018,295[2026-05-31].https://doi.org/10.1016/j.toxlet.2018.06.860.
[8] Babenko V,Babenko R,Gamieldien J,et al.FTO haplotyping underlines high obesity risk for European populations[J/OL].BMC Med Genomics,2019,12(Suppl.2)[2026-05-31].https://doi.org/10.1186/s12920-019-0491-x.
[9] Briones-Espinoza M J,Cortés-García J D,Vega-Cárdenas M,et al.Decreased levels and activity of Sirt1 are modulated by increased miR-34a expression in adipose tissue mononuclear cells from subjects with overweight and obesity:a pilot study[J].Diabetes Metab Syndr,2020,14(5):1347-1354.
[10] Worthmann A,John C,Rühlemann M C,et al.Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis[J].Nat Med,2017,23(7):839-849.
[11] Cheng Z L,Zhang L,Yang L,et al.The critical role of gut microbiota in obesity[J/OL].Front Endocrinol,2022,13[2026-05-31].https://doi.org/10.3389/fendo.2022.1025706.
[12] Tolhurst G,Heffron H,Lam Y S,et al.Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2[J].Diabetes,2012,61(2):364-371.
[13] Forbes S,Stafford S,Coope G,et al.Selective FFA2 agonism appears to act via intestinal PYY to reduce transit and food intake but does not improve glucose tolerance in mouse models[J].Diabetes,2015,64(11):3763-3771.
[14] Xiong Y M,Miyamoto N,Shibata K,et al.Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41[J].Proc Natl Acad Sci U S A,2004,101(4):1045-1050.
[15] Lee M J,Pramyothin P,Karastergiou K,et al.Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity[J].Biochim Biophys Acta BBA Mol Basis Dis,2014,1842(3):473-481.
[16] Tan H E,Sisti A C,Jin H,et al.The gut-brain axis mediates sugar preference[J].Nature,2020,580(7804):511-516.
[17] Drucker D J.GLP-1 physiology informs the pharmacotherapy of obesity[J/OL].Mol Metab,2022,57[2026-05-31].https://doi.org/10.1016/j.molmet.2021.101351.
[18] Neeland I J,Marso S P,Ayers C R,et al.Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk:a randomised,double-blind,placebo-controlled,clinical trial[J].Lancet Diabetes Endocrinol,2021,9(9):595-605.
[19] Kuriyama T,Ishibashi C,Kozawa J,et al.Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes[J].Clin Nutr ESPEN,2024,59:208-213.
[20] 卢军锋.生长分化因子15调控动物脂肪沉积的作用与机制[D].杨凌:西北农林科技大学,2024:86-87.
[21] International Diabetes Federation.The IDF consensus worldwide definition of the metabolic syndrome[Z].Brussels:IDF,2006.
[22] WS/T 428—2013 成人体重判定[S].
[23] Stevens J,Katz E G,Huxley R R.Associations between gender,age and waist circumference[J].Eur J Clin Nutr,2010,64(1):6-15.
[24] 中华人民共和国国家卫生健康委员会医政司.肥胖症诊疗指南(2024年版)[J].中华消化外科杂志,2024,23(10):1237-1260.
[25] Koliaki C,Spinos T,SpinouΜ,et al.Defining the optimal dietary approach for safe,effective and sustainable weight loss in overweight and obese adults[J/OL].Healthcare(Basel),2018,6(3)[2026-05-31].https://doi.org/10.3390/healthcare6030073.
[26] Liu D Y,Huang Y,Huang C,et al.Calorie restriction with or without time-restricted eating in weight loss[J].N Engl J Med,2022,386(16):1495-1504.
[27] Alzhrani N E,Bryant J M.Intermittent energy restriction combined with a high-protein/low-protein diet:effects on body weight,satiety,and inflammation:a pilot study[J].Obesities,2023,3(2):180-192.
[28] Findikoglu G,Altinkapak A,Yaylali G F.Is isoenergetic high-intensity interval exercise superior to moderate-intensity continuous exercise for cardiometabolic risk factors in individuals with type 2 diabetes mellitus?A single-blinded randomized controlled study[J].Eur J Sport Sci,2023,23(10):2086-2097.
[29] Wilding J P H,Batterham R L,Calanna S,et al.Once-weekly semaglutide in adults with overweight or obesity[J].N Engl J Med,2021,384(11):989-1002.
[30] Gastaldelli A,Cusi K,Fernández LandóL,et al.Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes(SURPASS-3 MRI):a substudy of the randomised,open-label,parallel-group,phase 3 SURPASS-3 trial[J].Lancet Diabetes Endocrinol,2022,10(6):393-406.
[31] Prillaman M.Obesity drugs aren't always forever.What happens when you quit[J].Nature,2024,628(8008):488-490.
[32] Wilding J P H,Batterham R L,Davies M,et al.Weight regain and cardiometabolic effects after withdrawal of semaglutide:the STEP 1 trial extension[J].Diabetes Obes Metab,2022,24(8):1553-1564.
[33] Aronne L J,Sattar N,Horn D B,et al.Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity:the SURMOUNT-4 randomized clinical trial[J].JAMA,2024,331(1):38-48.
[34] Kirwan J P,Courcoulas A P,Cummings D E,et al.Diabetes remission in the alliance of randomized trials of medicine versus metabolic surgery in type 2 diabetes(ARMMS-T2D)[J].Diabetes Care,2022,45(7):1574-1583.
[35] Mingrone G,Panunzi S,De Gaetano A,et al.Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes:10-year follow-up of an open-label,single-centre,randomised controlled trial[J].Lancet,2021,397(10271):293-304. |
|
|
|
